Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1006 of 6351
-
One-Pass clot removal device tested in major stroke study
Disease control Recruiting nowA prospective, open label study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
Sponsor: Vesalio • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug shows promise for psoriatic arthritis in major trial
Disease control OngoingThis is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .
Phase 3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immune cell therapy shows promise for BK virus in transplant kids
Disease control Recruiting nowBK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be safe and effective in decreasing specific viral load in children, adolescents and young adults (CAYA) with refractory BK infection post Allogeneic Hematopoietic Stem Cell …
Phase 1/2 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Radiation boost may extend life for bladder cancer patients with few remaining tumors
Disease control Recruiting nowThis is a Phase II, multicenter, randomized open-label and comparative study that has been designed to evaluate whether local consolidative radiotherapy in addition to standard of care improves overall survival as compared with standard of care in patients with regional and/or di…
Phase 2 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Higher dose of PAH drug may keep patients out of hospital longer
Disease control OngoingThe purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compa…
Phase 3 • Sponsor: Actelion • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for advanced cervical cancer: immune combo shows promise
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of tiragolumab in combination with atezolizumab and atezolizumab monotherapy in patients with programmed death-ligand 1 (PD-L1)-positive cervical cancer (metastatic and/or recurrent).
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Precision radiation: could a special scan improve prostate cancer treatment?
Disease control Recruiting nowThis is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Could repeat radiation save breasts after cancer returns?
Disease control Recruiting nowThe goal of the study is to investigate the feasibility of enabling a second chance for breast conservation in patients with in-breast recurrences after a previous lumpectomy and RT, investigators propose to test partial breast irradiation with the target volume encompassing the …
Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail targets Hard-to-Treat breast cancer
Disease control OngoingThe purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.
Phase 2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Melanoma trial mixes keytruda with new drugs to boost Pre-Surgery results
Disease control CompletedSubstudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02C is to evaluate the safety and efficacy of investigational treatment arms in participants …
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could your own fat help you walk again? new stem cell trial for paralysis
Disease control OngoingThe purpose of this research study is to investigate the safety and potential therapeutic effects of autologous, culture-expanded, adipose derived mesenchymal stem cell intrathecal injections in the treatment of spinal cord injury.
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Peanut allergy treatment shows promise in large study
Disease control OngoingThis is an open label observational single center study of clinical food oral immunotherapy outcomes with biomarker samples and participant and/or caregiver-completed questionnaires in participants between 6 months and 65 years of age with IgE-mediated peanut allergy undergoing f…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New antibiotic gel aims to stop surgical infections in their tracks
Prevention CompletedPhase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), compared to a SoC treated control arm, in prevention of post abdominal surge…
Phase 3 • Sponsor: PolyPid Ltd. • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
New hope for bile duct cancer: targeted drug shows promise in early trial
Disease control OngoingThis phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes nee…
Phase 2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental trio therapy takes on recurrent glioblastoma
Disease control OngoingThis is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be saf…
Phase 2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Housing first: a bold experiment to stop opioid addiction before it starts
Prevention CompletedHomeless youth have a much higher rate of substance use than non-homeless peers with evidence suggesting that homeless youth have the highest rates of opioid use among youth subgroups in the country (Brands et al., 2005); heroin using homeless youth also appear to have the highes…
Sponsor: Ohio State University • Aim: Prevention
Last updated Jun 26, 2026 17:04 UTC
-
New drug combo shows promise in shrinking advanced kidney tumors before surgery
Disease control OngoingThis phase II trial studies how well lenvatinib and pembrolizumab before surgery work in treating patients with kidney cancer that has spread from its original site of growth to nearby tissues or lymph nodes but has not spread to other places in the body (non-metastatic). Lenvati…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New hope for Crohn's: Long-Term drug study shows promise
Disease control OngoingThe reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New eye drug shows promise in slowing blindness from dry AMD
Disease control CompletedThe objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)
Phase 3 • Sponsor: IVERIC bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New biosimilar could offer cheaper Vision-Saving shots for wet AMD
Disease control CompletedThe purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration. Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group …
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 26, 2026 15:43 UTC